• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Eyenovia Inc.

    3/31/25 4:01:18 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email
    NT 10-K 1 tm251091d2_nt10k.htm NT 10-K

      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

     

    (Check one):

    x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D

    ¨ Form N-CEN ¨ Form N-CSR

       
     

    For Period Ended: December 31, 2024

    ¨ Transition Report on Form 10-K

    ¨ Transition Report on Form 20-F

    ¨ Transition Report on Form 11-K

    ¨ Transition Report on Form 10-Q

    For the Transition Period Ended: ____________________

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Eyenovia, Inc.
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    23461 South Pointe Drive, Suite 390
    Address of Principal Executive Office (Street and Number)
     
    Laguna Hills, CA 92653
    City, State and Zip Code

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      x   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
        (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
        (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

     

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Eyenovia, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”) by the March 31, 2025, filing deadline applicable to non-accelerated filers due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date, which is April 15, 2025.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

     

      Michael Rowe   833   393-6684
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes x No ¨
       
     
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes x No ¨
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Registrant expects to record a significant, non-cash impairment charge for the year ended December 31, 2024, due to the uncertainty associated with the Registrant’s current exploration of its strategic alternatives. The dollar amount of the impairment charge remains subject to internal review.

     

     

    Eyenovia, Inc. 

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2025  By: /s/ Michael Rowe, Chief Executive Officer

      

     

    Get the next $EYEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

      NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company's novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. Eyenovia continues to advance the Optejet UFD through Verification & Validation (V&V) studies to ensure that the device meets the st

      4/10/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

      Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform The combined company would continue marketing Eyenovia's FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a non-binding letter of inten

      3/20/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule. "Maintaining our Nasdaq listing, along with other steps we have taken to restructure the company and accelerate development of the user-filled Optejet, repre

      2/26/25 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Financials

    Live finance-specific insights

    See more
    • Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and webcast today, November 12th, at 4:30 pm ET NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing adv

      11/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

      NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714. To access t

      11/7/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced development collaborations with Formosa, Senju and SGN to leverage the Optejet for the $5 billion global dry eye disease market Company to host conference call and webcast today, August 12th, a

      8/12/24 4:05:00 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

      9/3/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

      NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs. Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Exec

      7/27/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

      NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations. Redwood City, CA Facility The Company today announced that its new manufacturing facility in Redwood City, CA is operational. The facility, which is located in close proximity to Silicon Valley-based vendors and customers, will primarily focus on Optejet® manufacturing finishing operations, including drug loading, label

      7/18/22 8:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eyenovia downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      11/18/24 7:44:30 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

      HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

      4/1/21 6:45:58 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Capital initiated coverage on Eyenovia with a new price target

      Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

      3/1/21 9:11:48 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    SEC Filings

    See more
    • Eyenovia Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      5/2/25 5:20:18 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      5/2/25 5:15:43 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Eyenovia Inc.

      10-K/A - EYENOVIA, INC. (0001682639) (Filer)

      4/30/25 4:05:54 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Strahlman Ellen R was granted 3,000 shares, increasing direct ownership by 176% to 4,706 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:58:58 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Palanki Ram was granted 3,000 shares, increasing direct ownership by 243% to 4,235 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:57:08 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Mather Charles E Iv was granted 8,000 shares, increasing direct ownership by 410% to 9,950 units (SEC Form 4)

      4/A - EYENOVIA, INC. (0001682639) (Issuer)

      4/29/25 7:56:40 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MYDCOMBI issued to EYENOVIA INC.

      Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/8/23 1:05:04 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      12/4/24 4:12:20 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

      SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

      11/14/24 5:08:44 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

      SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

      7/18/24 7:46:49 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/28/24 8:01:36 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/27/24 1:06:37 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      7/3/24 3:18:06 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care